Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy

(2019) Gilles Berger et al.   TRENDS IN MOLECULAR MEDICINE

Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma

(2019) Christopher B. Morse et al.   GYNECOLOGIC ONCOLOGY

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer

(2018) Tuo Li et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

(2018) Jung-Min Lee et al.   LANCET ONCOLOGY

Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage

(2018) Gillian Dunphy et al.   MOLECULAR CELL

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

(2018) Jianfeng Shen et al.   CANCER RESEARCH

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

(2018) Liya Ding et al.   Cell Reports

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

(2018) Roman M. Chabanon et al.   JOURNAL OF CLINICAL INVESTIGATION

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

(2017) Jung-Min Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

(2017) Ethan Brill et al.   Oncotarget

Monocyte and interferon based therapy for the treatment of ovarian cancer

(2016) Daniel S. Green et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Validation of a flow cytometry-based detection of γ-H2AX, to measure DNA damage for clinical applications

(2016) Pegah Johansson et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

(2016) Eileen E. Parkes et al.   JNCI-Journal of the National Cancer Institute

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

(2016) Qi Chen et al.   NATURE IMMUNOLOGY

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

(2016) Eileen E. Parkes et al.   JNCI-Journal of the National Cancer Institute

DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity

(2015) Anetta Härtlova et al.   IMMUNITY

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

(2015) C. King et al.   MOLECULAR CANCER THERAPEUTICS

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

(2015) P. A. Konstantinopoulos et al.   Cancer Discovery

Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21

(2015) Marianne K. Kim et al.   Oncotarget

Regulatory T cells in cancer immunotherapy

(2014) Hiroyoshi Nishikawa et al.   CURRENT OPINION IN IMMUNOLOGY

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

(2014) Gottfried E. Konecny et al.   JNCI-Journal of the National Cancer Institute

DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy

(2014) Melvin Lee Kiang Chua et al.   RADIATION AND ENVIRONMENTAL BIOPHYSICS

CHK2 kinase in the DNA damage response and beyond

(2014) L. Zannini et al.   Journal of Molecular Cell Biology

Checkpoint kinase 1 in DNA damage response and cell cycle regulation

(2013) Mallikarjun Patil et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2

(2013) Tracy X. Cui et al.   IMMUNITY

Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells

(2012) Z. Korwek et al.   DNA REPAIR

Monocytes control natural killer cell differentiation to effector phenotypes

(2011) K. Soderquest et al.   BLOOD

Cytokine release from innate immune cells: association with diverse membrane trafficking pathways

(2011) P. Lacy et al.   BLOOD

The DNA Damage Response Induces IFN

(2011) Sabrina Brzostek-Racine et al.   JOURNAL OF IMMUNOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Intraepithelial T cells and tumor proliferation

(2009) Sarah F. Adams et al.   CANCER

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

(2008) Ninke Leffers et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH